MCAD Deficiency (ACADM): Inheritance, Newborn Screening, and What a Positive Result Really Means

MCAD Deficiency (ACADM): Inheritance, Newborn Screening, and What a Positive Result Really Means

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: MCAD deficiency is one of the oldest and best-studied targets on newborn-screening panels in the United States and Canada. Large recent cohort studies, including a nationwide Italian program that screened nearly two million newborns, show that a flagged result is common, expected, and highly manageable. When it is caught early and managed by avoiding long fasts, most affected children have near-normal health and life expectancy. This guide grounds each reassurance in named research, but it does not replace your metabolic team or genetic counselor.

What you’ll learn:

• Why a “positive” newborn screen is a signal to confirm, not a diagnosis by itself.
• How MCAD deficiency is inherited and the real chance for siblings and future children.
• What day-to-day care actually looks like and why it works so well.
• What the diagnosis means for your wider family and for insurance in the US and Canada.

How MCAD Deficiency Is Inherited: The ACADM Gene

MCAD deficiency is a change in how the body burns fat for fuel. It is caused by variants in a gene called ACADM, which sits on chromosome 1. This gene holds the instructions for an enzyme, medium-chain acyl-CoA dehydrogenase. That enzyme breaks down medium-chain fats for energy when a person goes without food, which is exactly when the body must tap its fat stores.

The condition follows an autosomal recessive pattern. That means a child must inherit one non-working copy of ACADM from each parent to be affected. A person with only one non-working copy is a healthy carrier. This is why two healthy parents, each carrying one silent copy, can have an affected child.

Think of the enzyme like a backup generator. When meals stop, the generator should kick in and burn stored fat. In MCAD deficiency that generator is missing, so energy runs low during a fast, and the body cannot cover the gap between meals.

One variant does most of the work in some groups. The change written as c.985A>G (p.Lys329Glu) accounts for between 56% and 91% of disease-causing copies in people of Northern European ancestry. In a nationwide Italian cohort, this single variant appeared in 56 of 88 genotyped patients, about 63%. Many rarer variants exist and are catalogued in medical databases, which is why gene testing sometimes finds an unexpected combination.

Ancestry shapes which variant is likely. A 2025 cohort in Hefei, China found different hotspot variants, such as c.449-452del and c.1085G>A, rather than the European c.985A>G. That study also reported three novel ACADM variants not seen before. This is why a carrier test built for one ancestry can miss variants common in another.

Here is the math families ask about most. When both parents are carriers, each pregnancy has a 25% chance of an affected child and a 50% chance of a healthy carrier. The remaining 25% inherit two working copies. These odds reset with every pregnancy, like a coin flip, so a past unaffected child does not lower the risk for the next one.

Many parents ask how two healthy people “gave” this to their child. The honest answer is that no one did anything wrong. Carrier variants are silent and common, and they pass down quietly for generations until two carriers happen to have a child together. A genetic counselor can walk you through your own family’s odds; find one through the National Society of Genetic Counselors at NSGC.org.

Section recap: MCAD deficiency comes from two non-working ACADM copies, one from each carrier parent. Two carriers have a 25% chance of an affected child in each pregnancy.

Risk Magnitude: Turning Genetics Into Real Numbers

Screening programs give us solid numbers on how often MCAD deficiency appears. In the United States, MedlinePlus Genetics estimates about 1 in 17,000 people are affected. GeneReviews reports a birth prevalence of roughly one in 17,759. Put simply, this is uncommon but not rare.

Large cohorts refine this picture. The nationwide Italian program screened 1,976,473 newborns from 2019 to 2023 and found an incidence near 1 in 21,960 births. An English program that screened about 1.5 million babies found roughly 1 in 10,600. Rates vary by ancestry and by the screening thresholds each program uses. The table below lines up the main cohorts side by side:

Program / cohort	Newborns screened	Reported incidence
US estimate (MedlinePlus)	population estimate	about 1 in 17,000
US birth prevalence (GeneReviews)	population estimate	about 1 in 17,759
Italy, nationwide (2019–2023)	1,976,473	about 1 in 21,960
England	about 1.5 million	about 1 in 10,600
Hefei, China (2025)	880,224	about 1 in 55,014

Ancestry matters a lot here. MCAD deficiency is more common in people of Northern European ancestry than in other groups. A 2025 cohort in Hefei, China found only about 1 in 55,014 among 880,224 screened newborns, markedly lower. Being a carrier is far more common than being affected: roughly 1 in 40 to 1 in 100 people of Northern European ancestry carry one variant.

These different rates are not contradictions. Each program uses its own screening threshold, screens different populations, and defines a confirmed case a little differently. The English study, for example, used a specific C8 cutoff and counted milder biochemical cases, which nudges its rate higher. So treat any single number as a careful estimate, not an exact count.

Now separate two ideas that sound alike, because families often confuse them. The enzyme problem is present from birth in every affected child, so the biochemical trait is essentially always “on”. Doctors call this near-complete biochemical penetrance. But whether a child ever has a metabolic crisis depends heavily on avoiding triggers like long fasts.

That gap between “has the enzyme problem” and “has a crisis” is the whole reason screening plus prevention changes lives. Think of it like carrying an umbrella: the rain risk is real, but staying dry is largely in your control. The Italian cohort saw wide variability even among patients with the same genotype, and most stayed symptom-free. Your metabolic clinician can explain where your child sits in this picture.

Section recap: MCAD deficiency affects roughly 1 in 17,000 US births and is more common in Northern European ancestry. The enzyme deficiency is always present, but a crisis is largely preventable.

Testing Options: From the Heel-Prick Screen to a Diagnosis

For a newborn, the first test is a state or provincial newborn screening program. A heel-prick collects a dried blood spot, which a lab analyzes by tandem mass spectrometry. It looks for a raised level of a marker called C8 (octanoylcarnitine) and the C8/C10 ratio. MCAD deficiency is a core condition on the US Recommended Uniform Screening Panel, so every state screens for it.

A flagged screen is not a diagnosis. It triggers confirmatory testing at a specialist clinic. The ACMG confirmatory algorithm lays out exactly these steps after an elevated C8 result and sends the family to a metabolic specialist. The three confirmatory tests are:

• Plasma acylcarnitine profile — a blood test that measures the same fat-breakdown markers more precisely than the screen.
• Urine organic acids — a urine test that looks for byproducts that build up when fat cannot be burned.
• ACADM molecular genetic testing — a certified-lab gene test that identifies the exact variants.

What happens at the confirmatory visit is worth picturing ahead of time. The metabolic team will likely repeat a blood test for the acylcarnitine profile, collect urine for organic acids, and send blood for ACADM gene testing. These tests together separate a true diagnosis from a carrier or a false alarm. The clinic will also review feeding history and set a safe fasting schedule while results come back, so protection starts immediately rather than waiting on the genetics.

Screening is very good but not perfect, and that is by design. A screen is meant to catch as many affected babies as possible, which means it also flags some who turn out fine. In the English cohort, the screen’s positive predictive value was 77%, meaning many flagged babies are confirmed but a meaningful share are cleared. This is normal, expected, and exactly why the confirmatory appointment exists.

A direct-to-consumer report is a different tool entirely. The 23andMe MCAD Deficiency Carrier Status report is FDA-authorized under the consumer carrier-status framework first cleared in 2015. But it checks only four ACADM variants and is most useful for people of European descent. It is a carrier screen, not a diagnostic test: it cannot tell whether someone carries two variants and cannot assess a newborn’s risk of the condition.

Two limits deserve emphasis for a DTC-primed reader. First, a negative consumer result does not rule out rarer variants outside those four, so it cannot exclude carrier status. Second, the four-variant panel targets the European hotspot and can miss the different variants common in other ancestries, as the Hefei cohort’s distinct spectrum shows. Clinical labs such as Invitae or Color offer broader carrier and diagnostic panels ordered through a clinician. Bring any consumer report to your appointment, and lean on your metabolic team and a genetic counselor at NSGC.org to interpret it.

Section recap: A flagged newborn screen is a starting point that confirmatory clinic testing settles. A 23andMe carrier line is not the same as a state screen or a clinical diagnosis.

Making Sense of the Results You Hear

Families usually hear one of three outcomes, and knowing them in advance lowers the fear. An affected diagnosis means two pathogenic ACADM variants plus supporting biochemistry. Carrier status means one pathogenic variant in a healthy person, which still matters for future family planning. A variant of uncertain significance (VUS) is a change whose meaning is not yet clear.

The ACMG and AMP framework formalizes this into five tiers: pathogenic, likely pathogenic, VUS, likely benign, and benign. A VUS can be reclassified over time as evidence builds, which is why some families hear an uncertain result that later changes. Only the metabolic specialist can combine the biochemistry and the genetics into a firm answer, so an isolated variant line is never the whole story.

False-positive screens happen and are worth expecting. In the English program, about 70% of screen-detected cases had variants of definite importance while about 30% had variants of uncertain importance. Sometimes a flagged newborn screen is later cleared because the baby has a milder biochemical pattern that screening now picks up. The Italian cohort saw wide clinical variability even among patients with the very same genotype; most stayed symptom-free.

There is also a “mild” middle ground that modern screening now uncovers. As tandem mass spectrometry has grown more sensitive, it detects some babies with mild biochemical patterns who may never have classic disease. The Italian program’s wide clinical variability, even within one genotype, reflects this spectrum. Homozygous c.985A>G patients there had lower residual enzyme activity than compound heterozygotes, one clue among many the team weighs.

Think of a VUS like a word in a language the lab is still translating. Over time the meaning becomes clearer as more families and studies add data. Do not try to self-interpret a raw variant report. Ask your genetic counselor at NSGC.org to explain your child’s specific result rather than reading a general chart.

Section recap: The three outcomes are affected, carrier, and VUS. False-positive screens are common, and only the metabolic team turns test data into a diagnosis.

Prevention and Everyday Management: Why Screening Works

The heart of MCAD care is simple and powerful: avoid long fasts. GeneReviews gives concrete windows that lengthen as the child grows:

• Birth to 4 months: no more than 4 hours without feeding.
• From age 1: no fast longer than 12 hours.
• Older children: a bedtime snack often becomes the practical way to bridge overnight.

Your metabolic team sets the exact schedule for your child, since ages, weight, and situations all differ.

In infancy this means frequent feeds, so the baby never goes too long between meals. The bigger safeguard is a written emergency, or “sick-day,” protocol for times when the child is ill, vomiting, or not eating. A typical sick-day plan includes:

• Start carbohydrates early — extra sugary fluids or feeds at the first sign of illness.
• Watch for warning signs — unusual sleepiness, vomiting, or refusing food.
• Go to the emergency room fast if the child cannot keep food down.
• Hand over the letter so the team starts IV dextrose (sugar into a vein) without delay.

Dietary carnitine supplements are used selectively under specialist guidance, not for every child.

What does a metabolic crisis actually look like, so caregivers can act early? NORD describes these crises, marked by low blood sugar, unusual sleepiness, and vomiting, as precipitated by fasting or intercurrent illness. The plan is not to panic but to feed carbohydrates early and seek care quickly if the child cannot keep food down. Because the enzyme cannot make energy from stored fat, glucose becomes the essential fuel during illness, which is why early carbohydrates and IV dextrose work.

Think of the sick-day letter like a fire-escape map posted by the door. You hope never to need it, but it removes guesswork in a crisis. Keep copies with caregivers, daycare, grandparents, and in your phone. When you reach an emergency room, hand the letter over so the team knows to start IV dextrose without delay.

This is exactly why screening matters. Identified before symptoms, most children never have a crisis; the first fasting illness in an undiagnosed child was historically the danger point. GeneReviews notes newborn screening lowered neonatal-period mortality to between 0.6% and 2.4% in screened populations. Your primary care doctor and metabolic clinic, not this article, should hold your child’s plan; a genetic counselor at NSGC.org can help the wider family understand it.

Section recap: Core care is avoiding long fasts, feeding often, and following a written sick-day plan. Because of this, most screen-detected children never have a metabolic crisis.

The Latest Treatment and Research Landscape

Here is the honest state of therapy. As of 2026, there is no gene therapy and no disease-modifying drug approved specifically for MCAD deficiency. Neither the US Food and Drug Administration nor Health Canada has approved one. Management remains dietary and preventive. The one regulated product here is a screening-adjacent consumer test. The 23andMe carrier report is FDA-authorized only as a limited carrier screen, not a treatment. So do not be misled by unrelated “gene therapy” headlines.

The real progress is in evidence, not drugs. Recent large newborn-screening cohorts are refining incidence, genotype-phenotype links, and outcomes. The nationwide Italian program contributed data on 90 confirmed cases from nearly two million newborns. It showed that patients homozygous for c.985A>G had lower residual enzyme activity than compound heterozygotes. The 2025 Hefei, China cohort identified 31 variant alleles across 18 mutation types, including three novel variants, and confirmed a different variant spectrum than the European hotspot.

Long-term follow-up is the most reassuring evidence of all. A US cohort of 221 newborn-screened neonates linked early detection plus preventive management to predominantly normal or near-normal outcomes. That work documented the real-world care pathway of fasting avoidance and sick-day management applied after a positive screen. It aligns with international data, including Czech and Dutch cohorts, showing fewer acute brain-injury episodes and less intellectual disability after expanded screening.

In Canada, an Ontario population study characterized real-world health-services use among screen-detected children, grounding this care in a public-health system. It shows that MCAD deficiency care flows through provincial newborn-screening programs and metabolic clinics, with routine follow-up rather than crisis after crisis. The message across these datasets is consistent: caught early and managed well, this is a livable condition.

Why has the numbers-driven story mattered so much? Because it replaces fear with a track record. Newborn screening cut neonatal-period mortality dramatically compared with the pre-screening era, when the first fasting illness struck without warning. The English program, screening about 1.5 million babies, showed the screen reliably flags affected infants for early care. Each new cohort adds detail to a picture that already points the same direction.

Think of it this way: the “cure” here is a system, not a pill. Screening catches the condition, prevention avoids the crisis, and follow-up keeps children on track. That system already delivers excellent outcomes. Your metabolic team can tell you which current studies apply to your child, and a genetic counselor at NSGC.org can explain any new research you read about.

Section recap: No MCAD-specific drug or gene therapy is FDA- or Health Canada-approved as of 2026; care is dietary. Recent cohorts confirm near-normal outcomes with early detection and management.

Family Implications and Cascade Testing

A diagnosis in one child ripples through the family, because both parents of an affected child are obligate carriers. Each parent must carry one variant for the child to inherit two. That fact opens a structured next step called cascade testing: offering targeted ACADM testing to relatives who may share the variants.

Start with siblings. Each full sibling of an affected child has a 25% chance of being affected and a 50% chance of being a carrier. Testing them uses the family’s known variants, which makes it precise and fast, and it can bring real peace of mind either way. The parents’ own brothers and sisters, and their partners, may also want carrier testing for their own family planning.

Cascade testing is more efficient than starting from scratch. Once the family’s exact variants are known, relatives get a targeted test for those specific changes rather than a broad, slower panel. This lowers cost and speeds up answers. A genetic counselor usually works outward from the closest relatives, in roughly this order:

• Siblings first — each full sibling has a 25% chance of being affected and a 50% chance of being a carrier.
• The parents’ siblings and their partners — for their own family planning.
• More distant relatives — as the counselor judges useful, and can arrange testing across state or provincial lines.

Looking ahead, a genetic counselor can discuss reproductive options for future pregnancies, such as prenatal diagnosis and preimplantation genetic testing. An affected child’s own future children will be carriers or affected depending on the other parent’s carrier status. Because carrier frequency runs about 1 in 40 to 1 in 100 in Northern European ancestry, a partner’s status is not a trivial question. None of these choices are urgent or one-size-fits-all, which is exactly why a counselor, not a website, should guide them.

Think of cascade testing like tracing a family recipe: once you know the exact “ingredient” variants, you can check who else carries them. A board-certified genetic counselor, found through NSGC.org, should guide who to test and when, rather than this article.

Section recap: Both parents are carriers, so cascade testing is offered to siblings and relatives. A genetic counselor guides testing and reproductive options for the wider family.

Psychosocial and Practical Impact in the US and Canada

The worries after a screening scare are real, so let us address them with law and facts. The main US protection is the Genetic Information Nondiscrimination Act (GINA) of 2008. It bars health insurers from using genetic information for eligibility, coverage, or premiums. It also bars employers from using it in hiring, firing, or pay. That is strong protection for the two areas families fear most.

But know the gap. GINA does not cover life, disability, or long-term-care insurance. Its employment protections also do not apply to employers with fewer than 15 workers, though some states add their own rules. This gap is worth discussing with a counselor before buying certain policies.

There is nuance beyond the headline. GINA covers genetic information such as test results and family history. But it does not stop insurers from acting on a diagnosis once a condition is symptomatic and in the medical record. The Affordable Care Act helps close this gap for health plans by barring pre-existing-condition exclusions. Still, for the uncovered lines, some states add their own protections, so local rules matter.

Canada offers broader coverage. The Genetic Non-Discrimination Act of 2017 makes it a criminal offence to require or use genetic test results as a condition of a service or contract, including insurance. Unlike GINA, it extends across life, disability, and long-term-care insurance with no financial exceptions. The law also shields genetic information from employers, schools, landlords, and adoption agencies, and the Supreme Court of Canada upheld it in 2020. For a family in Ontario or Quebec, that is meaningful reassurance alongside provincial health coverage such as OHIP or RAMQ.

Cost is usually manageable through public and private coverage. In the US, follow-up and metabolic care are typically covered by Medicaid, CHIP, or ACA plans; in Canada, by provincial plans. The Ontario cohort confirms this care flows through provincial systems, with regular physician visits and hospital use tracked in a real population. Reassuringly, that study frames MCAD deficiency as an ongoing, managed condition rather than a string of emergencies.

Practically, share the written emergency protocol with school and daycare so caregivers know the plan. Think of it like an allergy action plan many schools already handle; MCAD care fits the same routine of a posted plan and trained adults. Patient-advocacy organizations also connect families with support and referral resources, which can ease the practical load.

Finally, the emotional weight is normal, and naming it helps. A screening scare is frightening, especially for a sleep-deprived new parent, and the evidence-based reassurance is that outcomes with modern management are excellent. The historically fatal reputation of this disorder came from the era before screening, when the first fasting illness struck without warning. That is not the world your screened baby lives in. If anxiety lingers, your primary care doctor and a genetic counselor at NSGC.org can help, and a metabolic social worker often can too.

Section recap: US GINA protects health insurance and jobs but not life, disability, or long-term-care policies; Canada’s 2017 law covers those too. Costs are usually covered, and anxiety is a normal, treatable part of a screening scare.

Frequently Asked Questions

Will my baby definitely get the disease? A flagged newborn screen is not a diagnosis; it triggers confirmatory testing that distinguishes an affected child, a healthy carrier, and a false positive. In fact, in one large program only about 70% of screen-detected cases had variants of definite importance. Even in an affected child, the enzyme problem is present but a metabolic crisis is largely preventable with early, consistent management. Your metabolic team will give you the specific answer for your baby.

Will my other children or future babies inherit it? MCAD deficiency is autosomal recessive. When both parents are carriers, each full sibling has a 25% chance of being affected and a 50% chance of being a carrier. Each future pregnancy carries the same 25% chance and resets like a coin flip. A past unaffected child does not lower the next one’s risk. Cascade testing and a genetic counselor at NSGC.org can clarify each relative’s status and discuss options for future pregnancies.

Will this affect my child’s health, life, or insurance later? In the US, GINA protects health insurance and employment but not life, disability, or long-term-care insurance. In Canada, the 2017 Genetic Non-Discrimination Act extends protection across those insurance lines. Discuss specific policies with a counselor before deciding.

My 23andMe report mentioned MCAD carrier status — is that the same as this diagnosis? No. The 23andMe report checks only four ACADM variants and is a carrier screen, not a diagnostic test. It cannot confirm a diagnosis or assess a newborn’s risk, and a negative result cannot rule out rarer variants. A state newborn screen followed by confirmatory clinic testing is the actual diagnostic pathway.

Should I get a second opinion or genetic counseling? Yes, seeking a genetic counselor is standard and encouraged, especially for interpreting results and planning family testing. Find a board-certified counselor through NSGC.org, and ask your metabolic clinic about a second specialist opinion if you want one. Second opinions are routine in rare-disease care and should not offend your team.

Summary

MCAD deficiency is an autosomal recessive fatty-acid oxidation disorder caused by two non-working ACADM copies. It affects roughly 1 in 17,000 US births and is a core newborn-screening target across the US and Canada. A flagged screen is a signal to confirm, not a verdict, and confirmatory testing separates affected children from carriers and false positives. Day-to-day care centers on avoiding long fasts and following a written sick-day plan, which is why most screen-detected children stay healthy. No MCAD-specific drug or gene therapy is approved by the FDA or Health Canada as of 2026. Even so, recent cohorts and long-term follow-up confirm near-normal outcomes with early detection and management. For the wider family, cascade testing and a genetic counselor guide next steps, and US and Canadian law offers meaningful, if different, protection against genetic discrimination.

Here is a short checklist to bring to the confirmatory appointment. Write down your baby’s exact feeding schedule and any illnesses since birth. Note whether either parent has known carrier status, including any 23andMe or clinical result. The team can then interpret it against the four-variant limit of consumer tests. Ask for the written sick-day protocol, the safe fasting window for your baby’s age, and a referral to a genetic counselor at NSGC.org. Ask, too, whether siblings should be tested and how. The clinic’s answers, grounded in the same evidence summarized here, will replace fear with a concrete plan.

Above all, remember the direction of travel. Newborn screening exists precisely because catching MCAD deficiency before the first fasting illness turns a historically dangerous disorder into a managed one. Cohorts spanning the US, Italy, England, China, and Canada point the same way: found early and managed well, children do well.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Chang KJ, Lam CW, Vockley J. Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. GeneReviews, University of Washington / NCBI Bookshelf (last update 2024-09-26). https://www.ncbi.nlm.nih.gov/books/NBK1424/
2. Ruoppolo M, et al. Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) Newborn Screening in Italy: Five Years’ Experience from a Nationwide Program. International Journal of Neonatal Screening (2025). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12550940/
3. Medium-chain acyl-CoA dehydrogenase deficiency. MedlinePlus Genetics, NIH National Library of Medicine. https://medlineplus.gov/genetics/condition/medium-chain-acyl-coa-dehydrogenase-deficiency/
4. Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) — Newborn Screening. Baby’s First Test / HRSA-supported Newborn Screening Clearinghouse. https://www.babysfirsttest.org/newborn-screening/conditions/medium-chain-acyl-coa-dehydrogenase-deficiency-mcadd
5. Oerton J, Khalid JM, Besley G, et al. Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency in England. Journal of Medical Screening (2011). https://pmc.ncbi.nlm.nih.gov/articles/PMC3243649/
6. Zhang Y, Ma X, et al. Prevalence and Mutation Analysis of Medium-Chain Acyl-CoA Dehydrogenase Deficiency Detected by Newborn Screening in Hefei, China. International Journal of Neonatal Screening (2025). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12471205/
7. Merritt JL, et al. 221 Newborn-Screened Neonates with Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency: Findings from the Inborn Errors of Metabolism Collaborative. Molecular Genetics and Metabolism (2016). https://pmc.ncbi.nlm.nih.gov/articles/PMC5031545/
8. Genetic Discrimination and the Genetic Information Nondiscrimination Act (GINA) of 2008. National Human Genome Research Institute / NIH. https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
9. 23andMe Carrier Status report for MCAD Deficiency (ACADM). 23andMe / U.S. FDA. https://medical.23andme.com/reports/carrier-status/
10. American College of Medical Genetics and Genomics (ACMG) ACT Sheets & Algorithms; Richards S, et al. Standards and Guidelines for the Interpretation of Sequence Variants. Genetics in Medicine (2015). https://pubmed.ncbi.nlm.nih.gov/25741868/
11. Medium Chain Acyl-CoA Dehydrogenase Deficiency. National Organization for Rare Disorders (NORD). https://rarediseases.org/rare-diseases/medium-chain-acyl-coa-dehydrogenase-deficiency/
12. Genetic Non-Discrimination Act (S.C. 2017, c. 3). Parliament of Canada. https://laws-lois.justice.gc.ca/eng/annualstatutes/2017_3/page-1.html
13. Chan A, Karaceper MD, Chakraborty P, et al. Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario, Canada. Orphanet Journal of Rare Diseases (2019). https://link.springer.com/article/10.1186/s13023-019-1001-0

Last updated: 2026-08-11

Author: genelumen editorial team. This article aggregates 13 sources from peer-reviewed medical literature and public health agencies (tier 1=11 / tier 2=2), including NIH, CDC, Health Canada, ACMG guidelines, and PubMed-indexed publications.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Related: Genetic Diseases category

🌐 日本語版: MCAD欠損症は遺伝する？｜ACADM遺伝子・新生児マススクリーニング・保因者の意味を研究データで整理